Frontiers in cardiovascular medicine · 2026
Early detection value of miR-29a in patients with acute myocardial infarction.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yanqing, Gao Peng, Duan Yawei, Su Hanqi, Wu Haibo, Jia Yuan, Zhang Yue, Liu Jia, Li Hongxiao, Li Xiangming, Li Wenjuan, Shi Xiaoshuai, Liu Tingting, Huang Teng, Du Rongpin
Аннотация
BACKGROUND: Early detection of myocardial remodeling, a critical precursor to heart failure in acute myocardial infarction (AMI), remains inadequate with current biomarkers. Preclinical studies suggest miR-29a plays a role in these processes, yet its diagnostic value in early AMI remains unclear. This study evaluates the diagnostic and prognostic potential of miR-29a as a marker for myocardial remodeling in AMI patients.
METHODS: A prospective cohort study enrolled 52 patients with ST-elevation myocardial infarction (STEMI) caused by anterior descending branch occlusion, who underwent primary percutaneous coronary intervention within 12 h of symptom onset, along with 39 healthy controls.
RESULTS: Serum miR-29a levels were significantly elevated in STEMI patients compared to controls, exhibiting a graded increase with higher SYNTAX scores. MiR-29a levels positively correlated with soluble suppression of tumorigenicity 2 (sST2), N-terminal pro-brain natriuretic peptide (NT-proBNP), and the Tei index, while showing an inverse correlation with left ventricular ejection fraction (LVEF). Receiver operating characteristic (ROC) analysis indicated that serum miR-29a holds promise as a novel biomarker for early detection of myocardial remodeling in AMI. Furthermore, the combination of miR-29a with NT-proBNP and/or sST2 significantly enhanced diagnostic accuracy compared to individual biomarkers. The triad of miR-29a, NT-proBNP, and sST2 achieved the highest area under the curve (AUC) of 0.904, with 97.4% specificity and 76.9% sensitivity.
CONCLUSION: Serum miR-29a shows significant potential as a biomarker for the early detection of myocardial remodeling in AMI, providing valuable diagnostic and prognostic insights.
METHODS: A prospective cohort study enrolled 52 patients with ST-elevation myocardial infarction (STEMI) caused by anterior descending branch occlusion, who underwent primary percutaneous coronary intervention within 12 h of symptom onset, along with 39 healthy controls.
RESULTS: Serum miR-29a levels were significantly elevated in STEMI patients compared to controls, exhibiting a graded increase with higher SYNTAX scores. MiR-29a levels positively correlated with soluble suppression of tumorigenicity 2 (sST2), N-terminal pro-brain natriuretic peptide (NT-proBNP), and the Tei index, while showing an inverse correlation with left ventricular ejection fraction (LVEF). Receiver operating characteristic (ROC) analysis indicated that serum miR-29a holds promise as a novel biomarker for early detection of myocardial remodeling in AMI. Furthermore, the combination of miR-29a with NT-proBNP and/or sST2 significantly enhanced diagnostic accuracy compared to individual biomarkers. The triad of miR-29a, NT-proBNP, and sST2 achieved the highest area under the curve (AUC) of 0.904, with 97.4% specificity and 76.9% sensitivity.
CONCLUSION: Serum miR-29a shows significant potential as a biomarker for the early detection of myocardial remodeling in AMI, providing valuable diagnostic and prognostic insights.